Analyst Price Targets — AZN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 10, 2025 11:14 am | — | HSBC | $216.00 | $179.64 | TheFly | AstraZeneca price target raised to $108 from $95 at HSBC |
| December 3, 2025 11:30 am | — | Morgan Stanley | $206.00 | $180.34 | TheFly | AstraZeneca price target raised to $103 from $93 at Morgan Stanley |
| July 9, 2025 7:38 pm | Luisa Hector | Berenberg Bank | $194.00 | $141.64 | TheFly | AstraZeneca price target raised to $97 from $93 at Berenberg |
| November 13, 2024 1:13 pm | Etzer Darout | BMO Capital | $176.00 | $162.38 | StreetInsider | AstraZeneca (AZN) PT Lowered to $88 at BMO Capital |
| September 11, 2024 8:18 am | Etzer Darout | BMO Capital | $178.00 | $159.88 | StreetInsider | BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN) |
| May 30, 2024 7:07 am | John Eade | Argus Research | $170.00 | $153.68 | StreetInsider | AstraZeneca (AZN) PT Raised to $85 at Argus |
| May 28, 2024 9:20 am | Etzer Darout | BMO Capital | $164.00 | $153.48 | StreetInsider | BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN) |
| July 12, 2023 8:44 am | Andrew Berens | Leerink Partners | $158.00 | $129.72 | Benzinga | These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts |
| January 5, 2023 7:01 am | — | BMO Capital | $164.00 | $139.00 | Benzinga | BMO Capital Initiates Coverage On AstraZeneca with Outperform Rating, Announces Price Target of $82 |
| November 11, 2022 3:58 am | — | Leerink Partners | $156.00 | $130.18 | Benzinga | SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $78 |
Latest News for AZN
The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.
AstraZeneca (AZN) shares fell roughly 8% as the market opened on July 9, 2026. Investors who held AZN and lost money are examining whether the losses tied to this collapse may be recoverable.
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed EGFR therapy.
On July 27, AstraZeneca PLC will report its results for the second quarter of 2026. As a reminder, its revenue rose 12.5% year-over-year to $15.29 billion in Q1. Enhertu, one of the key growth drivers of AstraZeneca's oncology franchise, generated $831 million in revenue in Q1, up 39.4% YoY and 4.1% QoQ.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.